Article
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
British journal of haematology - 1 Jan 2014
Deininger Michael W, Kopecky Kenneth J, Radich Jerald P, Kamel-Reid Suzanne, Stock Wendy, Paietta Elisabeth, Emanuel Peter D, Tallman Martin, Wadleigh Martha, Larson Richard A, Lipton Jeffrey H, Slovak Marilyn L, Appelbaum Frederick R, Druker Brian J
Abstract excerpt
The standard dose of imatinib for newly diagnosed patients with chronic phase chronic myeloid leukaemia (CP-CML) is 400 mg daily (IM400), but the optimal dose is unknown. This randomized phase II study compared the rates of molecular, haematological and cytogenetic response to IM400 vs. imatinib 400 mg twice daily (IM800) in 153 adult patients with CP-CML. Dose adjustments for toxicity were flexible to maximize...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.